Xenetic Biosciences (XBIO)
(Delayed Data from NSDQ)
$3.59 USD
+0.02 (0.56%)
Updated Aug 9, 2024 10:10 AM ET
3-Hold of 5 3
C Value F Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
XBIO 3.59 +0.02(0.56%)
Will XBIO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for XBIO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for XBIO
Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates
ElectroCore, Inc. (ECOR) Reports Q2 Loss, Tops Revenue Estimates
XBIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Xenetic Biosciences (XBIO) Reports Q1 Loss, Misses Revenue Estimates
Xenetic Biosciences (XBIO) Reports Q2 Loss, Tops Revenue Estimates
Oncternal Therapeutics (ONCT) Reports Q2 Loss, Lags Revenue Estimates
Other News for XBIO
Xenetic Biosciences Announces Executive Leadership Restructuring
Xenetic Biosciences appoints James Parslow as interim CEO
Xenetic names James Parslow as interim CEO
Xenetic Biosciences, Inc. Announces Executive Leadership Transition
Xenetic Biosciences reports Q1 results